543322 Stock Overview Glenmark Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Alivus Life Sciences Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Alivus Life Sciences Historical stock prices Current Share Price ₹1,017.85 52 Week High ₹1,335.00 52 Week Low ₹627.25 Beta 0.16 1 Month Change -6.10% 3 Month Change -11.55% 1 Year Change 58.40% 3 Year Change 67.20% 5 Year Change n/a Change since IPO 36.04%
Recent News & Updates
Price target increased by 10% to ₹1,139 Nov 08
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Oct 25
Glenmark Life Sciences Limited to Report Q2, 2025 Results on Oct 24, 2024 Oct 17
Glenmark Life Sciences Limited Approves Interim Dividend for the Financial Year 2023-24 Sep 26
Investor sentiment deteriorates as stock falls 15% Sep 24
Price target increased by 9.6% to ₹1,084 Sep 16 See more updates
Price target increased by 10% to ₹1,139 Nov 08
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Oct 25
Glenmark Life Sciences Limited to Report Q2, 2025 Results on Oct 24, 2024 Oct 17
Glenmark Life Sciences Limited Approves Interim Dividend for the Financial Year 2023-24 Sep 26
Investor sentiment deteriorates as stock falls 15% Sep 24
Price target increased by 9.6% to ₹1,084 Sep 16
Investor sentiment improves as stock rises 23% Sep 10
Glenmark Life Sciences Limited, Annual General Meeting, Sep 25, 2024 Sep 03
Glenmark Life Sciences Limited, Annual General Meeting, Sep 25, 2024 Sep 02
First quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat Jul 26
Glenmark Life Sciences Limited to Report Q1, 2025 Results on Jul 25, 2024 Jul 18
Price target increased by 8.6% to ₹933 May 25
High number of new directors May 15
Full year 2024 earnings: EPS and revenues miss analyst expectations Apr 26
Glenmark Life Sciences Limited Announces Resignation of Gita Nayyar as Non-Executive, Independent Director Apr 23
Glenmark Life Sciences Limited to Report Q4, 2024 Results on Apr 25, 2024 Apr 20
Nirma Limited completed the acquisition of 75% stake in Glenmark Life Sciences Limited (NSEI:GLS) from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) (GPL). Mar 14 Nirma Limited completed the acquisition of 75% stake in Glenmark Life Sciences Limited (NSEI:GLS) from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) (GPL). Mar 13
Glenmark Life Sciences Limited Announces Board Resignations, Effective March 6, 2024 Mar 06
Investor sentiment deteriorates as stock falls 16% Mar 06
Insufficient new directors Mar 01
Price target increased by 17% to ₹801 Jan 25
Third quarter 2024 earnings released: EPS: ₹9.69 (vs ₹8.57 in 3Q 2023) Jan 24
Glenmark Life Sciences Limited to Report Q3, 2024 Results on Jan 23, 2024 Jan 16
Second quarter 2024 earnings released: EPS: ₹9.69 (vs ₹8.72 in 2Q 2023) Oct 21
Glenmark Life Sciences Limited to Report Q2, 2024 Results on Oct 20, 2023 Oct 14
Glenmark Life Sciences Limited Declares Interim Equity Dividend for the Financial Year 2023-24, Payable on or After October 23, 2023 Oct 11
Glenmark Life Sciences Limited Approves Interim Dividend for the Financial Year 2022-23 Sep 27 Glenmark Life Sciences Limited announced that it expects to receive INR 56.515658085 billion in funding Glenmark Life Sciences Limited announced that it expects to receive INR 56.515658085 billion in funding Glenmark Life Sciences Limited Proposes Final Dividend for the Financial Year 2022-2023 Sep 02
Glenmark Life Sciences Limited, Annual General Meeting, Sep 26, 2023 Aug 25
ChrysCapital Still in Race to Buy Controlling Stake in Glenmark Life Sciences Aug 17
Nirma Reportedly Closes in on Glenmark's API Arm Aug 01
First quarter 2024 earnings: EPS exceeds analyst expectations Jul 22
Nirma, Sekhmet Pharmaventures Reportedly Vie for $731 Million Glenmark Life Stake Jul 15
Glenmark Life Sciences Limited to Report Q1, 2024 Results on Jul 21, 2023 Jul 14
Sekhmet Pharmaventures Reportedly Competes with Nirma Group to Acquire Glenmark Life Sciences Jun 15
Sekhmet, Nirma Reportedly in Fray for Glenmark's API Biz Jun 14
Nirma, 3 Private Equity Firms Reportedly in Race to Buy Glenmark Life Sciences May 25
Price target increased by 9.0% to ₹584 May 02
Full year 2023 earnings: EPS and revenues exceed analyst expectations Apr 28
Third quarter 2023 earnings released: EPS: ₹8.57 (vs ₹8.65 in 3Q 2022) Jan 28
Glenmark Life Sciences Limited to Report Q3, 2023 Results on Jan 27, 2023 Jan 14
Price target decreased to ₹562 Nov 16
High number of new directors Nov 16
High number of new directors Nov 02
Price target decreased to ₹562 Oct 31
Consensus EPS estimates fall by 13% Oct 28
Glenmark Life Sciences Limited Announces Executive Changes Oct 22
Second quarter 2023 earnings released: EPS: ₹8.72 (vs ₹9.83 in 2Q 2022) Oct 22
Glenmark Life Sciences Limited to Report Q2, 2023 Results on Oct 21, 2022 Oct 15
Upcoming dividend of ₹10.50 per share Sep 08
Glenmark Life Sciences Limited, Annual General Meeting, Sep 26, 2022 Aug 24
First quarter 2023 earnings released: EPS: ₹8.87 (vs ₹9.36 in 1Q 2022) Aug 05
Glenmark Life Sciences Limited to Report Q1, 2023 Results on Aug 04, 2022 Jul 23
High number of new directors Apr 27 Glenmark Life Sciences Limited Announces Executive Changes
Glenmark Life Sciences Limited to Report Q4, 2022 Results on Apr 20, 2022 Apr 14
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Feb 09
Non-Executive Director recently bought ₹5.0m worth of stock Nov 18 Shareholder Returns 543322 IN Pharmaceuticals IN Market 7D -1.6% -0.2% -1.9% 1Y 58.4% 43.4% 24.7%
See full shareholder returns
Return vs Market: 543322 exceeded the Indian Market which returned 24.7% over the past year.
Price Volatility Is 543322's price volatile compared to industry and market? 543322 volatility 543322 Average Weekly Movement 6.1% Pharmaceuticals Industry Average Movement 5.9% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.1%
Stable Share Price: 543322 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 543322's weekly volatility (6%) has been stable over the past year.
About the Company Glenmark Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies.
Show more Alivus Life Sciences Limited Fundamentals Summary How do Alivus Life Sciences's earnings and revenue compare to its market cap? 543322 fundamental statistics Market cap ₹124.63b Earnings (TTM ) ₹4.24b Revenue (TTM ) ₹22.05b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 543322 income statement (TTM ) Revenue ₹22.05b Cost of Revenue ₹10.32b Gross Profit ₹11.73b Other Expenses ₹7.50b Earnings ₹4.24b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 34.56 Gross Margin 53.21% Net Profit Margin 19.21% Debt/Equity Ratio 0%
How did 543322 perform over the long term?
See historical performance and comparison Dividends
2.2% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/19 22:09 End of Day Share Price 2024/12/19 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Alivus Life Sciences Limited is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Saad Shaikh BOB Capital Markets Ltd. Neha Manpuria BofA Global Research Nitin Agarwal DAM Capital Advisors
Show 6 more analysts 
